|Enanta Pharmaceuticals, Inc.|
500 Arsenal Street
United States - Map
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
|Dr. Jay R. Luly Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Paul J. Mellett Jr.,
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Fin. & Admin.
|Dr. Yat Sun Or Ph.D.,
Chief Scientific Officer and Sr. VP of R&D
|Dr. Ly Tam Phan Ph.D.,
Director of Medicinal Chemistry
|Dr. Zhe Wang Ph.D.,
Director of Chemistry
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|